I found the last paragraph to be interesting because of it's connection to our current Type II trial.

"The second study showed that over four years of continuous treatment using Afresa as their only mealtime insulin, adult patients with type 2 diabetes achieved sustained glycemic control reflected by low A1c's, without significant changes in pulmonary function."

http://www.diabeteshealth.com/read/2009/10/05/6393/afresa-a-new-insulin-by-the-way-its-inhaled/